Jump to Main Content

Meetings

Friday Satellite Symposia

ASH is looking forward to Friday Satellite Symposia (FSS) in 2021! More information about the program, updated FSS Guidelines and how to apply will be available in February. FSS are industry-supported, CME-certified symposia . These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.

The 2020 FSS were broadcast live on, Friday, December 4 according to the schedule below. Not all sessions are available on demand yet, but you may refer to individual listings of sessions for information on their future availability as determined by each corporate host. Virtual programs will be available on demand after the scheduled presentation, and according to the release information listed under each session, for a period of 1 week up to 90 days.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. Please review the official FSS guidelines to learn about hosting a symposium.

For more information, contact Kelly Cade, ASH FSS Manager, Consultant, at fss@hematology.org.


  • Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Multiple Myeloma (Part 1 of a 4-Part Series)

    This program is supported by Abbvie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm, Oncopeptides, Sanofi Genzyme and Takeda Oncology

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific time

    This activity, the first of a 4-part live webinar series, will feature 5 multiple myeloma (MM) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions & scenarios related to the management of MM. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    On demand activity expected to be available here mid-January 2021. 

    Chair:

    Neil Love, MD
    Research To Practice
    Miami,  FL

    Speakers:

    Rafael Fonseca, MD
    Division of Hematology and Oncology, Mayo Clinic
    Scottsdale,  AZ

    Ola Landgren, MD, PhD
    Memorial Sloan-Kettering Cancer Center
    New York,  NY

    Nikhil C. Munshi, MD
    Dana-Farber Cancer Institute
    Boston,  MA

    Robert Z. Orlowski, MD,PhD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Edward A. Stadtmauer, MD, FACP
    Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
    Philadelphia,  PA

    Sylvia Eriksen , Research To Practice
    Email: bmoss@researchtopractice.com

    ACCESS PROGRAM HERE

    Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine

    This program is supported by Cleveland Clinic & AAMDS

    Friday, December 04, 2020
    7:00 a.m. - 10:00 a.m. Pacific time

    The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present the symposium, Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine. This CME-certified activity provides an in-depth and up-to-date review of research related to the management and treatment strategies for patients with MDS, AML, myeloproliferative neoplasms, and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

    On demand activity expected to be available here in January 2021. For program questions, please contact: pringls@ccf.org

    Chair:

    Bhumika J. Patel, MD
    Cleveland Clinic
    Cleveland,  OH

    Speakers:

    Kelly L. Bolton, MD, PhD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Vikas Gupta, MD, FRCP, FRCPath
    Princess Margaret Cancer Centre, University Health Network
    Toronto,  ON, Canada

    Betty K. Hamilton, MD
    Cleveland Clinic Foundation
    Cleveland,  OH

    Jeffrey E. Lancet, MD
    H. Lee Moffitt Cancer Center & Research Institute
    Tampa,  FL

    Jaroslaw P. Maciejewski, MD, PhD
    Cleveland Clinic
    Cleveland,  OH

    Guillermo F Sanz, MD, PhD
    Hematology Department, Hospital Universitario y Politécnico La Fe
    Valencia,  Spain

    Samantha Pringle , Cleveland Clinic
    Email: pringls@ccf.org

    ACCESS PROGRAM HERE

  • Accelerating Toward a Cure for Myeloma: Emerging Data, New Agents, and an Evolving Treatment Paradigm

    This program is supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm & Oncopeptides. Provided by the Annenberg Center for Health Sciences at Eisenhower. In partnership with Clinical Care Options, LLC & the International Myeloma Foundation.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific time

    Attendees of this annual International Myeloma Foundation/Clinical Care Options cosponsored program can expect to gain practical insights from a panel of experts as they discuss new therapeutic advances along with their personal approaches for myeloma care. This international panel will focus on evolving worldwide standards of care and will also provide their perspectives on promising agents that may soon change practice. As part of panel discussion, the experts will debate clinical questions, review available evidence and challenges that affect therapeutic decisions, and then share their individual treatment recommendations for each case. Throughout the program, learners will be able to vote on case scenarios and submit questions directly to the panel for their consideration. Discussion topics include:

    Case Discussion 1: Early Treatment for High-Risk Smoldering MM

    Case Discussion 2: Individualized Approaches to Frontline Treatment Selection

    Case Discussion 3: Managing the Patient With Relapsed Disease After = 1 Lines of Therapy

    Case Discussion 4: Understanding the Different Anti-BCMA Therapies

    Panel Discussion: Future Directions and a New 2021 Treatment Algorithm for MM

    On demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) Friday, March 19. For program questions, please contact: meetings@clinicaloptions.com

    Chair:

    Brian G.M. Durie, MD
    Cedars Sinai Cancer Center
    Los Angeles,  CA

    Speakers:

    Shaji K. Kumar, MD
    Mayo Clinic Rochester, Division of Hematology
    Rochester,  MN

    Thomas Martin, MD
    University of California
    San Francisco,  CA

    Philippe Moreau, MD
    Nantes University Hospital
    Nantes,  France

    S. Vincent Rajkumar, MD
    Mayo Clinic
    Rochester,  MN

    Jesús F. San-Miguel
    University of Navarra
    Pamplona,  Spain

    Clinical Care Options , Clinical Care Options, LLC
    Email: meetings@clinicaloptions.com

    ACCESS PROGRAM HERE

    Advances in Therapy for Inherited Non-Malignant Blood Disorders: Focus on Sickle Cell Disease and Hemophilia.

    This program is supported by an educational grant from Novo Nordisk Inc. This continuing medical education activity is provided by Vindico Medical Education.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific time

    This continuing medical education symposium will address continuing and emerging educational needs in the care and management of patients with sickle cell disease or hemophilia. Experts in the field will provide didactic presentations and panel discussion on these rare non-malignant blood orders to address the tremendous burden of disease that occurs in these patients and provide guidance to integrate current and emerging management strategies into the clinic to enhance patient care and quality of life. The safety and efficacy of recent therapeutic advances will also be evaluated to provide insight into their integration into the treatment decision process and to ensure optimal, individualized patient care.

    On demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) Friday, March 19. For program questions, please contact: CME@VindicoCME.com

    Chair:

    Steven W. Pipe, MD
    University of Michigan
    Ann Arbor,  MI

    Speakers:

    Biree Andemariam, MD
    University of Connecticut
    Farmington,  CT

    Christine Guelcher, Hemostasis RN-BC, MS, PPCNP-BC
    Center for Cancer and Blood Disorders
    Washington,  DC

    Mark Reding, MD
    University of Minnesota Medical Center
    Minneapolis,  MN

    CME Resource , Vindico Medical Education
    Email: CME@VindicoCME.com

    ACCESS PROGRAM HERE

    Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL

    This program is supported by educational grants from ADC Therapeutics, Epizyme Inc., Incyte Corporation, Kite, A Gilead Company, and MorphoSys US Inc.

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific time

    Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are two of the more common non-Hodgkin lymphomas (NHLs); these aggressive and indolent disorders represent the two classic “faces” of lymphoma. Recently, several novel therapeutic classes, including targeted agents, next-generation antibodies, and CAR-T cell therapy, have emerged as active strategies in diverse DLBCL and FL settings. These developments have challenged the use of standard immunochemotherapy-focused management and led to a new era of care in which increasingly, baseline factors can help identify patients who may benefit from the use of innovative therapeutics.

    This live web broadcast will provide learners with a clinical grounding on how new science is changing FL and DLBCL management. Each scientific seminar will open with a case-based “Tumor Board” session that will explore important factors in the selection and use of newer therapeutics, followed by a concise expert take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive NHL. Register today to learn how the experts are rising to the challenge of modern patient management for aggressive and indolent NHL. Don’t miss this informative event!

    On demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) Friday, March 19. For program questions, please contact: Questions@PeerView.com

    Chair:

    Nathan H. Fowler, MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Prof. Dr. Martin Dreyling, MD
    LMU Hospital
    Munich,  Germany

    Caron Jacobson, MD, MMSc
    Harvard Medical School
    Boston,  MA

    Krish Patel, MD
    Swedish Cancer Institute
    Seattle,  WA

    PVI Live , PeerView Institute for Medical Education
    Email: Questions@PeerView.com

    ACCESS PROGRAM HERE

    Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)

    This program is supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC

    Friday, December 04, 2020
    11:00 a.m. - 2:00 p.m. Pacific time

    This activity, the second of a 4-part live webinar series, will feature 5 chronic lymphocytic leukemia (CLL) investigators serving as the faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of CLL. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    On demand activity expected to be available here mid-January 2021.

    Chair:

    Neil Love, MD
    Research To Practice
    Miami,  FL

    Speakers:

    Paul M. Barr, MD
    Medical Director, Clinical Trial Office, Professor of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center
    Rochester,  NY

    Matthew S. Davids, MD
    Harvard Medical School
    Boston,  MA

    Kerry A. Rogers, MD
    The Ohio State University
    Columbus,  OH

    Tanya Siddiqi, MD
    City of Hope Cancer Center
    Duarte,  CA

    Stephan Stilgenbauer, Professor Dr
    Saarland University Medical Center
    Homburg,  Germany

    Sylvia Eriksen , Research To Practice
    Email: bmoss@researchtopractice.com

    ACCESS PROGRAM HERE

  • Adopting New Approaches for Relapsed/Refractory Follicular Lymphoma

    This program is supported by an independent educational grant from Epizyme, Inc.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific time

    Join us for Trivia Night! Compete against your peers through case-based challenges about relapsed/refractory follicular lymphoma. Test your skills selecting treatment and managing side effects as well as your knowledge of novel and emerging therapies. This will be a lively symposium with panel discussion and clinical pearls.

    On demand activity expected to be available here on January 15, 2021. For program questions, please contact: jharden@medscapelive.com

    Chair:

    Loretta J. Nastoupil, MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Connie Lee Batlevi, MD, PhD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Matthew A. Lunning, DO, FACP
    University of Nebraska Medical Center
    Omaha,  NE

    Jaye Harden , MedscapeLIVE!
    Email: jharden@medscapelive.com

    ACCESS PROGRAM HERE

    Applying Data to Practice: The Role of BTK Inhibitors for the Treatment of CLL

    This program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific time

    Join us for this interactive, case-based, symposium where you can test your knowledge and skills using BTK inhibitors for the treatment of patients with treatment-naïve and relapsed/refractory CLL.  Using a tumor board approach, the panel will discuss real-world examples and will put the trial data for BTK inhibitors into clinical context. The audience will vote on treatment choices for patients and how they would manage treatment-related side effects.  The panel will discuss best practices for recognizing and mitigating side effects of BTK inhibitors. The symposium will also include future directions for BTK inhibitors, such as novel agents and investigational combinations.

    On demand activity expected to be available here on January 15, 2021. For program questions, please contact: jharden@medscapelive.com

    Chair:

    Jennifer Woyach, MD
    The Ohio State University, Comprehensive Cancer Center
    Columbus,  OH

    Speakers:

    John N. Allan, MD
    Weill Cornell Medicine
    New York,  NY

    Deborah M. Stephens, DO
    University of Utah/Huntsman Cancer Institute
    Salt Lake City,  UT

    Jaye Harden , MedscapeLIVE!
    Email: jharden@medscapelive.com

    ACCESS PROGRAM HERE

    Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Acute Myeloid Leukemia (Part 3 of a 4-Part Series)

    This program is supported by Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific time

    This activity, the third of a 4-part live webinar series, will feature 5 acute myeloid leukemia (AML) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of AML. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    On demand activity expected to be available here mid-January 2021. 

    Chair:

    Neil Love, MD
    Research To Practice
    Miami,  FL

    Speakers:

    Mark Levis, MD, PhD
    Director, Adult Leukemia Program, Co-Division Director, Hematologic Malignancies, Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine
    Baltimore,  MD

    Alexander E. Perl, MD
    University of Pennsylvania
    Philadelphia,  PA

    Daniel A. Pollyea, MD
    University of Colorado Denver
    Aurora,  CO

    Eytan M. Stein, MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Andrew H Wei, MBBS, PhD
    The Alfred Hospital
    Melbourne,  Australia

    Sylvia Eriksen , Research To Practice
    Email: bmoss@researchtopractice.com

    ACCESS PROGRAM HERE

    Evolving the Standard of Care: Rethinking the Treatment Paradigm for Iron Deficiency Anemia

    This program is supported by an independant educational grant from Pharmacosmos Therapeutics, Inc.

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific time

    Iron deficiency anemia (IDA) continues to be a significant public health burden leading to a number of adverse health outcomes. Although oral iron is traditionally viewed as fist-line therapy, this is largely due to perceived safety issues with older intravenous (IV) iron formulations. Newer IV iron formulations show comparable efficacy and safety to oral agents, which may present a more convenient and cost-effective treatment option for the management of IDA.

    Join our panel of top experts for an interactive, virtual, CME-certified symposium providing up-to-date information for the treatment of iron deficiency anemia, including the pathophysiology of IDA in order to accurately identify and diagnose patients at increased risk. The efficacy and safety of different iron replacement formulations will also be discussed to inform the selection of the appropriate therapy to optimize the management of patients.?

    On demand activity expected to be available here on January 15, 2021. For program questions, please contact: jharden@medscapelive.com

    Chair:

    Carlo Brugnara, MD
    Harvard Medical School, Boston Children's Hospital
    Boston,  MA

    Speakers:

    Michael Auerbach, MD, FACP
    Auerbach Hematology and Oncology
    Baltimore,  MD

    Myles Wolf, MD, MMsc
    Duke University School of Medicine
    Durham,  NC

    Jaye Harden , MedscapeLIVE!
    Email: jharden@medscapelive.com

    ACCESS PROGRAM HERE

    Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma

    This program is supported by GlaxoSmithKline, Janssen, Oncopeptides

    Friday, December 04, 2020
    3:00 p.m. - 6:00 p.m. Pacific time

    Clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This live streamed educational symposium will involve 4 world renowned experts actively engaged in the management of patients with Multiple Myeloma.  Join us and listen to the experts debate the most pressing topics in MM. Polling questions, short didactic sessions, and Q&A opportunities will also be provided. Don’t forget to visit BioAscend.com to view an accredited videotaped discussion highlighting the most clinically relevant data presented which will be available 4 to 6 weeks after the symposium.

    On demand activity available here until January 28 at 11:59 p.m. PST. For program questions, please contact: dunnam@bioascend.com

    Chair:

    Sagar Lonial, MD
    Winship Cancer Institute of Emory University
    Atlanta,  GA

    Speakers:

    Kenneth Anderson, MD
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
    Boston,  MA

    Pieter Sonneveld, MD, PhD
    Department of Hematology, Erasmus MC Cancer Institute
    Rotterdam,  Netherlands

    Peter Voorhees, MD
    Levine Cancer Institute, Atrium Health
    Charlotte,  NC

    Chloe Dunnam , Bio Ascend
    Email: dunnam@bioascend.com

    ACCESS PROGRAM HERE

  • Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Hodgkin and Non-Hodgkin Lymphoma (Part 4 of a 4-Part Series)

    This program is supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics Inc and Seattle Genetics

    Friday, December 04, 2020
    7:00 p.m. - 10:00 p.m. Pacific time

    This activity, the fourth of a 4-part live webinar series, will feature 5 lymphoma investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a pre-survey to ascertain their perspectives on controversial questions/scenarios related to the management of Hodgkin and NHL, including FL, mantle cell and DLBCL.  Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.

    For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.

    On demand activity expected to be available here mid-January 2021.

    Chair:

    Neil Love, MD
    Research To Practice
    Miami,  FL

    Speakers:

    Jonathan W. Friedberg, MD, MSSc
    James P. Wilmot Cancer Center
    Rochester,  NY

    John Kuruvilla, MD
    Princess Margaret Cancer Centre
    Toronto,  Canada

    Ann S. LaCasce, MD, MSc
    Dana-Farber Cancer Institute
    Boston,  MA

    John P. Leonard, MD
    Weill Cornell Medical College
    Pelham Manor,  NY

    Michael E. Williams, MD
    University of Virginia Health System
    Charlottesville,  VA

    Sylvia Eriksen , Research To Practice
    Email: bmoss@researchtopractice.com

    ACCESS PROGRAM HERE

    Improving Outcomes in MDS and MPN: Tailoring Treatment Based on Patient- and Disease-Specific Factors

    This program is supported by educational grants from Agios Pharmaceuticals, Inc.; Astex Pharmaceuticals, Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Taiho Oncology, Inc.; and Takeda Oncology

    Friday, December 04, 2020
    7:00 p.m. - 10:00 p.m. Pacific time

    This live program is designed to update physicians on the latest advancements in the clinical management of MDS and MPNs, including current approaches, diagnostic strategies, anemia management, and novel therapies under investigation for these diseases. In addition, this program will use case studies to apply recent findings to real-world case scenarios and will allow participants to reflect on how they might handle each scenario.

    On demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) March 19. For program questions, please contact: dkleinstein@gotoper.com

    Chair:

    Guillermo Garcia-Manero, MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Ruben Mesa, MD
    UT Health San Antonio Cancer Center
    San Antonio,  TX

    Valeria Santini
    AOU Careggi-University of Florence
    Firenze,  Fi, Italy

    Ayalew Tefferi, MD
    Mayo Clinic
    Rochester,  MN

    Dayna Kleinstein , Physicians' Education Resource® (PER®)
    Email: info@gotoper.com

    ACCESS PROGRAM HERE